ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025
Rhea-AI Summary
ProPhase Labs (NASDAQ: PRPH), a biotech, genomics and consumer products company, has scheduled a virtual conference call to present its full year 2024 financial results on March 31, 2025, at 11:00 AM EST. The presentation, hosted by Renmark Financial, will include the company's financial performance and a review of current company strategy.
A press release containing detailed financial results will be issued before the virtual conference call. Stakeholders, investors, and other interested parties are invited to register and attend the live event through Renmark Financial's platform. A replay of the presentation will be made available on ProPhase's investor website following the event.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – PRPH
On the day this news was published, PRPH declined 4.17%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
GARDEN CITY, NY, March 27, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that they will be presenting full year 2024 financial results, and a review of current Company strategy, on a virtual conference call hosted by Renmark Financial on March 31, 2025 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on the company’s investor website.
REGISTER HERE: https://www.renmarkfinancial.com/events/fourth-quarter-year-end-2024-results-virtual-conference-call-nasdaq-prph-PA3S8FxovQ
- To ensure smooth connectivity, please access this link using the latest version of Google Chrome.
About ProPhase Labs
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our goal is to create a healthier world with bold action and the power of insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value.
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
investorrelations@prophaselabs.com
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman
212-812-7680
Jboidman@renmarkfinancial.com
